Vesicular Monoamine Transporter (VMAT) Modulators for Parkinson's Disease

Vesicular Monoamine Transporter (VMAT) Modulators

<div class="infobox infobox-company">
<div class="infobox-header">VMAT Modulator Pipeline</div>
<div class="infobox-row"><strong>Target:</strong> VMAT2</div>
<div class="infobox-row"><strong>Status:</strong> Approved (TD), PD (emerging)</div>
<infobox-row><strong>Mechanism:</strong> VMAT2 inhibition</div>
</div>

Overview

The vesicular monoamine transporter 2 (VMAT2, encoded by SLC18A2) packages dopamine and other monoamines into synaptic vesicles for storage and release. VMAT2 modulators reduce available synaptic dopamine, making them useful for hyperkinetic movement disorders, with emerging applications in Parkinson's disease[@vmat_biology].

VMAT Biology

VMAT2 is essential for monoamine neurotransmission:

• Packages dopamine into synaptic vesicles
• Protects monoamines from enzymatic degradation
• Regulates quantal dopamine release

Approved VMAT2 Inhibitors

Valbenazine (Neurocrine/Ingrezza)

| Attribute | Details |
|-----------|---------|
| Company | Neurocrine Biosciences |
| Product | Ingrezza |
| Indication | Tardive Dyskinesia (approved), HD (Phase 3) |
| Mechanism | Selective VMAT2 inhibitor |
| Status | Approved 2017 |

Valbenazine was the first FDA-approved drug specifically for tardive dyskinesia. It provides sustained VMAT2 inhibition with once-daily dosing[@vmat_td].

Deutetrabenazine (Teva/Austedo)

Vesicular Monoamine Transporter (VMAT) Modulators

<div class="infobox infobox-company">
<div class="infobox-header">VMAT Modulator Pipeline</div>
<div class="infobox-row"><strong>Target:</strong> VMAT2</div>
<div class="infobox-row"><strong>Status:</strong> Approved (TD), PD (emerging)</div>
<infobox-row><strong>Mechanism:</strong> VMAT2 inhibition</div>
</div>

Overview

The vesicular monoamine transporter 2 (VMAT2, encoded by SLC18A2) packages dopamine and other monoamines into synaptic vesicles for storage and release. VMAT2 modulators reduce available synaptic dopamine, making them useful for hyperkinetic movement disorders, with emerging applications in Parkinson's disease[@vmat_biology].

VMAT Biology

VMAT2 is essential for monoamine neurotransmission:

• Packages dopamine into synaptic vesicles
• Protects monoamines from enzymatic degradation
• Regulates quantal dopamine release

Approved VMAT2 Inhibitors

Valbenazine (Neurocrine/Ingrezza)

| Attribute | Details |
|-----------|---------|
| Company | Neurocrine Biosciences |
| Product | Ingrezza |
| Indication | Tardive Dyskinesia (approved), HD (Phase 3) |
| Mechanism | Selective VMAT2 inhibitor |
| Status | Approved 2017 |

Valbenazine was the first FDA-approved drug specifically for tardive dyskinesia. It provides sustained VMAT2 inhibition with once-daily dosing[@vmat_td].

Deutetrabenazine (Teva/Austedo)

| Attribute | Details |
|-----------|---------|
| Company | Teva Pharmaceutical |
| Product | Austedo |
| Indication | Huntington's disease, Tardive Dyskinesia |
| Mechanism | VMAT2 inhibitor (deuterated) |
| Status | Approved 2017 |

Deutetrabenazine uses deuterium substitution to improve pharmacokinetics and reduce dosing frequency compared to tetrabenazine.

VMAT in Parkinson's Disease

Clinical Application

While VMAT2 inhibitors are not approved for PD, they have potential applications:

| Application | Rationale |
|-------------|-----------|
| Dyskinesia management | Reduce dopamine signaling |
| OFF episode control | Modulate dopamine release |
| Combination therapy | Adjunct to levodopa |

Research Programs

| Company | Focus | Stage |
|---------|-------|-------|
| Neurocrine | HD chorea → PD potential | Phase 3 |
| Teva | TD in PD patients | Research |
| Various | Novel VMAT2 modulators | Discovery |

VMAT2 as Drug Target

Mechanism of Action

VMAT2 inhibitors work by:

Therapeutic Effects

| Disorder | Effect |
|----------|--------|
| Tardive Dyskinesia | Reduces involuntary movements |
| Huntington's Disease | Reduces chorea |
| Potential PD | May reduce dyskinesia |

Emerging VMAT2 Programs

Novel VMAT2 Modulators

Several companies are developing next-generation VMAT2 targeting compounds:

| Company | Program | Focus | Stage |
|---------|---------|-------|-------|
| Neurocrine | Valbenazine extensions | HD, PD | Phase 3 |
| Teva | Deutetrabenazine analogs | Improved PK | Preclinical |
| Research institutions | VMAT2 PET agents | Imaging | Research |

VMAT2 Imaging

| Company | Product | Application |
|---------|---------|-------------|
| Life Molecular Imaging | VMAT2 PET tracers | Diagnostic imaging |
| Roche | VMAT2 ligands | Research |

Comparison with Other Dopaminergic Targets

| Target | Mechanism | PD Application |
|--------|-----------|----------------|
| VMAT2 | Reduce dopamine release | Emerging (dyskinesia) |
| MAO-B | Block dopamine breakdown | Established (Azilect, Zelapar) |
| COMT | Block peripheral metabolism | Established (Ongentys, Stalevo) |
| DAT | Block reuptake | Research |
| D1/D2 receptors | Direct activation | Established (agonists) |

Related Mechanisms

• [Dopamine Metabolism](/mechanisms/dopamine-metabolism)
• [Dopamine Vesicular Cycling](/mechanisms/dopamine-pathway)
• [Tardive Dyskinesia](/diseases/tardive-dyskinesia)
• [Huntington's Disease](/diseases/huntingtons)

Cross-References

• [Neurocrine Biosciences](/companies/neurocrine-biosciences)
• [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)
• [PD Pipeline](/companies/pd-pipeline)
• [Mechanism Index](/companies/mechanism-index)
• [Continuous Dopaminergic Stimulation](/companies/continuous-dopaminergic-stimulation)

External Links

• [PubMed - VMAT2](https://pubmed.ncbi.nlm.nih.gov/)
• [FDA - Ingrezza](https://www.fda.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Vesicular Monoamine Transporter (VMAT) Modulators for Parkinson's Disease discovered through SciDEX knowledge graph analysis: